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Abstract
Introduction Signal transducer and activator of transcription
(STAT) 5b is a transcription factor involved in pro-proliferative
and pro-survival signaling in a number of solid tumors, including
breast cancer. The contribution of STAT5b to breast cancer cell
motility has not been explored. This work aims to elucidate the
role of STAT5b in breast cancer cell migration.
Methods STAT5b was knocked down by using siRNA in two
aggressive, highly migratory breast cancer cell lines (BT-549
and MDA-MB-231), and transwell migration assays were
performed to determine the importance of STAT5b for their
migration. Knockdown-rescue experiments were used to
validate the specificity of STAT5b knockdown and to determine
which regions/functions of STAT5b are necessary for its role in
migration. Live-cell imaging of wound healing and spreading
was carried out to examine cell morphology and motility after
STAT5b knockdown.
Results Knockdown of STAT5b, but not STAT5a, inhibited
migration of BT-549 and MDA-MB-231 breast cancer cells to
serum by 60% to 80%, and inhibited migration equally over a
range of serum concentrations (0.1% to 10% serum). Migratory
inhibition upon STAT5b knockdown could be rescued by
reintroduction of wild-type STAT5b, as well as Y699F- and
dominant-negative STAT5b mutants, but not an SH2 domain
defective R618K-STAT5b mutant. β1- integrin-mediated
migration of breast cancer cells to fibronectin was inhibited with
STAT5b knockdown, and loss of STAT5b correlated with loss of
directional migration and formation of multiple, highly contractile
protrusions upon attachment to fibronectin.
Conclusions The data presented here demonstrate that
STAT5b is integral to breast cancer cell migration and identify a
novel, SH2-dependent function of STAT5b in regulating β1-
integrin-mediated migration of highly aggressive breast cancer
cells.
Introduction
Breast cancer is the second most common cancer in Ameri-
can women. Despite improvements in detection and the devel-
opment of new treatment strategies, the American Cancer
Society estimates that more than 180,000 new cases of
breast cancer will be diagnosed, and more than 40,000
women will die of breast cancer this year alone. Because many
cancers arise from dysregulation of signaling pathways found
in normal cells, one of the difficulties in treating cancers is
identifying cancer-specific therapeutic targets. Current tar-
geted therapies have not been as successful as anticipated.
This lack of success is due in part to the ability of cancer cells
to upregulate alternative signaling pathways to promote
growth and tumor progression. Many tumorigenic signaling
pathways converge on common nuclear transcription factors,
and therefore, targeting these downstream proteins may be
more effective [1].
BSA: bovine serum albumin; DMEM: Dulbecco's modified eagle's medium; DMSO: dimethyl sulfoxide; dn: dominant-negative; EGF: epidermal growth 
factor; EGFR: epidermal growth factor receptor; F: phenylalanine; FBS: fetal bovine serum; FN: fibronectin; GFP: green fluorescent protein; GH: 
growth hormone; HA: hemagglutinin; K: lysine; LPA: lysophosphatidic acid; PBS: phosphate-buffered saline; Prl: prolactin; R: arginine; RFP: red flu-
orescent protein; SCCHN: squamous cell carcinoma of the head and neck; SH2: Src homology domain 2; STAT: signal transducer and activator of 
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One such group of transcription factors is the signal trans-
ducer and activator of transcription (STAT) family. STATs are
a family of transcription factors activated by cytokines or
growth factors or both. Seven members of the STAT family are
known: STAT 1, 2, 3, 4, 5a, 5b, and 6. STAT proteins are latent
in the cytoplasm and require phosphorylation of a conserved
C-terminal tyrosine residue for activation. This allows dimeriza-
tion to occur between the phosphorylated tyrosine of one
STAT and the Src homology 2 (SH2) domain of another.
Active dimers are translocated to the nucleus, where they bind
DNA and regulate gene transcription. STAT proteins regulate
transcription of genes involved in a variety of biologic proc-
esses, including proliferation, survival, and angiogenesis, all of
which are involved in cancer development and progression.
Thus, it is not surprising that in the last several years, a role for
STATs in tumorigenesis has emerged. Activation of STAT5a
and STAT5b occurs in a variety of cancers including both
hematopoietic cancers and solid tumors, such as those of the
breast, prostate, lung, head and neck, and brain [2,3]. STAT5a
and STAT5b regulate the transcription of the pro-proliferative
genes c-myc and cyclin D1 and the anti-apoptotic genes Bcl-
xL and Pim-1, to stimulate tumor growth and survival [4-8]. In
addition, STAT5b has been implicated in prostate cancer cell
invasion [9].
To date, most of the work examining STAT5b in breast cancer
has focused on its pro-proliferative function, and its role in
breast cancer cell migration has not been examined. Impor-
tantly, a recent study investigating the effects of STAT5a on
breast cancer cell migration and invasion showed that prolac-
tin (Prl)-induced activation of STAT5a inhibited migration and
invasion of BT-20 and T-47D human breast cancer cells [10].
STAT5a and STAT5b, although highly homologous, are
encoded by two separate genes and function independently in
mammary gland development. STAT5a is necessary for lobu-
loalveolar outgrowth and lactation mediated by Prl signaling,
whereas STAT5b is vital for establishing growth hormone
(GH)-directed sexual dimorphism [11,12].
Given this background, we sought to investigate the potential
role of STAT5b, specifically, in the migration of two highly
aggressive, highly migratory breast cancer cell lines. We found
that STAT5b knockdown inhibited serum- and fibronectin-
stimulated migration of both BT-549 and MDA-MB-231
human breast cancer cell lines in a transwell assay. This inhi-
bition was rescued by co-expression of wild-type, Y699F-, and
dominant-negative STAT5b but not STAT5b containing a
mutation in the SH2 domain. With real-time imaging, we
showed that knockdown of STAT5b resulted in decreased
directional migration and the formation of multiple protrusions,
giving rise to an overall reduction in motility. These results
establish, for the first time, an important SH2-dependent func-
tion of STAT5b in aggressive breast cancer, further defining its
role in tumorigenesis and supporting its potential as a thera-
peutic target for the treatment of breast cancer.
Materials and methods
Cell culture
BT-549 and MDA-MB-231 human breast cancer cell lines
were obtained from the American Type Culture Collection
(Manassas, VA). Cells were passaged twice per week and
maintained in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS). All tissue-
culture reagents were purchased from Invitrogen (Gaithers-
burg, MD).
siRNA Transfection
BT-549 and MDA-MB-231 cells were transfected with siGE-
NOME SMARTpool siRNA targeting human STAT5b or indi-
vidual custom oligonucleotides specific for STAT5a or
STAT5b (siGENOME STAT5b SMARTpool duplex #3), or
luciferase duplex control, all purchased from Dharmacon
(Lafayette, CO). Transfections were performed by using either
Oligofectamine (Invitrogen) or Amaxa nucleofection (Amaxa/
Lonza, Walkersville, MD), by using solution T and program X-
013 (MDA-MB-231 cells) or A-023 (BT-549 cells) as per man-
ufacturers' instructions. For knockdown-rescue experiments,
cells were transfected simultaneously with siSTAT5b SMART-
pool duplex #3 and HA-tagged wild-type-, Y699F-, dominant-
negative-, or R618K-STAT5b engineered to be immune to
knockdown by introduction of four silent point mutations in the
siRNA target sequence. These point mutations were intro-
duced by using QuikChange site-directed mutagenesis (Strat-
agene, La Jolla, CA), and constructs were sequenced to verify
mutations.
Immunoblotting
Cells were lysed in RIPA buffer (150 mmol/L NaCl, 50 mmol/
L Tris, pH 7.4, 1% deoxycholate, 1% Triton X-100, 5 mmol/L
EDTA) containing protease inhibitor cocktail (Calbiochem,
San Diego, CA) and sodium orthovanadate (Sigma, St. Louis,
MO), and boiled in 2× Laemmli buffer containing β-mercap-
toethanol or 20 mmol/L dithiothreitol for 5 minutes at 100°C.
Protein lysates were separated on 7.5% or 12.5% polyacryla-
mide gels and transferred to nitrocellulose (Pall Corporation,
Pensacola, FL). Membranes were blocked and incubated with
primary antibodies in TBST (150 mmol/L NaCl, 0.1% Tween
20, 50 mmol/L Tris, pH 8.0) containing 5% nonfat dry milk or
3% BSA. STAT5a- and STAT5b-specific polyclonal antibod-
ies were developed by our laboratory, as previously described
[13]. Monoclonal anti-β-actin antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). HA monoclonal
antibody was obtained from the University of Virginia hybrid-
oma facility. Secondary antibodies were applied in TBST and
were HRP-conjugated sheep anti-mouse or donkey anti-rabbit
(GE Healthcare, Piscataway, NJ). The enhanced chemilumi-
nescence detection kit (GE Healthcare) was used to detect
antibody binding. Acrylamide was from Bio-Rad (Hercules,
CA), prestained molecular weight standards were from Sigma,
and all other reagents were of reagent or molecular biologic
grade from Sigma.Available online http://breast-cancer-research.com/content/11/4/R52
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Transwell migration assays
BT-549 and MDA-MB-231 cells were transfected with siRNA,
as described earlier. Seventy-two hours after transfection, 5 ×
104 BT-549 cells or 1 × 105 MDA-MB-231 cells were plated
in serum-free (DMEM/0.1% BSA) media into the upper cham-
bers of BD BioCoat Control Chambers (BD Biosciences, San
Jose, CA), and DMEM containing 0 to 10% FBS was placed
in the lower chamber. For β1-integrin blocking experiments,
cells were pretreated for 1 hour with DMSO (vehicle control)
or 10 μg/ml monoclonal anti-human β1-integrin antibody (R&D
Systems, Minneapolis, MN), and treatment was left on for the
duration of the assay. For migration to extracellular matrix com-
ponents, the undersides of filters were coated with 0 to10 μg/
ml human plasma fibronectin (FN) (BD Biosciences) or recom-
binant human vitronectin (VN) (R&D Systems) overnight at
4°C, as indicated, and DMEM/0.1% BSA was used in both the
upper and lower chambers. Plates were incubated at 37°C,
and migration was allowed to proceed for 3 to 6 hours. After
this time, nonmigratory cells in the upper chambers were
removed with cotton swabs, and the remaining cells were
stained with 0.1% crystal violet (Sigma) in 20% ethanol. Cells
were counted by using a Zeiss Invertoskop light microscope.
Four fields were counted on each of two filters. Results are
expressed as average cells per field or relative migration (com-
pared with control).
Wound healing
Cell were plated on FN-coated (5 μg/ml) 35-mm Bioptechs
delta T dishes (Fisher Scientific, Pittsburgh, PA). Confluent
cell monolayers were wounded by using a 20-μl pipette tip,
and cells migrating into the wound were filmed at 37°C with
time-lapse microscopy by using a Nikon TE200 inverted
microscope with a 20× differential interference contrast
objective and a Bioptechs heated stage. Images were taken
with a Hamamatsu Orca camera every 5 minutes for 6 hours
and collected with Openlab software (Improvision, Lexington,
MA). Movies were analyzed by using Image J Manual Tracking
software (National Institutes of Health, Bethesda, MD). Single
cell nuclei were tracked over time, and migratory speed was
calculated by dividing the length of the migration path by the
total movie time. Directional persistence was determined as
the net displacement divided by the total length of the migra-
tion path.
Total internal reflection fluorescence (TIRF) microscopy
Cells were transfected with siRNA oligonucleotides, mKO-
paxillin, and GFP-speckle-actin by using Amaxa nucleofection,
as described earlier. Seventy-two hours after transfection,
cells were plated on FN (2 μg/ml), and after 20 to 30 minutes
of spreading, TIRF images were acquired by using an inverted
microscope, 60× objective (Olympus, model IX70). GFP was
excited by using the 488-nm laser line of an Ar ion laser, and
RFP was excited by using the 543-nm laser line of an He-Ne
laser (Mells Griot, Carlsbad, CA). Time-lapse images were
taken every 3 seconds for 5 minutes with a charge-coupled
device camera (QImaging, Surrey, BC, Canada) and analyzed
by using MetaMorph (MDS Analytical Technologies, Missis-
sauga, Ontario, Canada). Protrusion rates were determined by
using ImageJ Kymograph software (National Institutes of
Health) and calculated as the length of the protrusion divided
by the total time of the movie.
Results
STAT5b knockdown inhibits breast cancer cell migration
To determine the importance of STAT5b for breast cancer cell
migration, we used siRNA transfection to knock down
STAT5b in the highly migratory BT-549 breast cancer cell line.
Knockdown of STAT5b to virtually undetectable levels in these
cells inhibited their migration to serum by approximately 70%
(Figure 1A). To ensure that this effect was not unique to one
cell line, we tested the effect of STAT5b siRNA knockdown on
migration of MDA-MB-231 cells, another highly aggressive,
migratory breast cancer cell line. In these cells, knockdown of
STAT5b also inhibited migration to serum, by approximately
50% (Figure 1A).
It is well established that STAT5b promotes cell-cycle pro-
gression and survival of breast cancer cells [14-19]. To deter-
mine whether knockdown of STAT5b affected proliferation or
survival under the conditions of our migration experiments, we
performed trypan blue assays on knockdown cells 72 hours
after transfection. In both BT-549 and MDA-MB-231 cells,
knockdown of STAT5b did not significantly alter the total
number of adherent cells or the viability of adherent cells over
a 6-hour period, which is the maximum length of our transwell
migration assays (data not shown). Thus, we conclude that the
inhibition of migration after knockdown of STAT5b is not a
result of secondary effects on adherence, viability, or survival.
By using BT-549 cells, we determined the optimal migration
conditions for trans-well assays to be the migration to 1%
serum over a 3-hour period. Because these cells require a low
dose of serum to migrate, we used them to determine whether
increasing concentrations of serum could overcome the effect
of STAT5b knockdown. As seen in Figure 1B, migration to
serum was dose dependent, with 3% to 10% serum being
optimal. Knockdown of STAT5b significantly inhibited migra-
tion of BT-549 cells by 60% to 80% at all serum concentra-
tions. Similar results were obtained in the MDA-MB-231 cells
(data not shown). Thus, increasing the concentration of serum
components did not overcome the effect of STAT5b knock-
down on inhibiting migration. However, migration was not
completely abrogated after knockdown of STAT5b in either
cell line. The cells retained their capacity to migrate at a similar
"basal" level across all serum concentrations tested. This indi-
cates that both STAT5b-dependent and STAT5b-independent
pathways may be responsible for migration of these cells to
serum.Breast Cancer Research    Vol 11 No 4    Bernaciak et al.
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Figure 1
STAT5b knockdown inhibits breast cancer cell migration STAT5b knockdown inhibits breast cancer cell migration. (a) BT-549 or MDA-MB-231 breast cancer cells were transfected with no siRNA (con), 
control siRNA for luciferase (siLuc), siSTAT5b SMARTpool (BT-549 cells), or siSTAT5b SMARTpool duplex #3 (MDA-MB-231 cells). Seventy-two 
hours after transfection, cells were plated in serum-free media in trans-well chambers. Media containing 1% fetal bovine serum (FBS; BT-549) or 
10% FBS (MDA-MB-231) were placed in the lower chambers. After 3 hours (BT-549) or 6 hours (MDA-MB-231), cells were fixed, stained with crys-
tal violet, and the number of migratory cells was counted. Results are graphed as the average number of migratory cells per field ± SEM. One-way 
ANOVA with Tukey's post-test was used to determine statistical significance (P < 0.05) between the following: BT-549: con and siSTAT5b (*), 
siLuc and siSTAT5b (black circles); n = 5. MDA-MB-231: con and siSTAT5b (*), siLuc and siSTAT5b (black circles); n = 4. (b) BT-549 breast can-
cer cells were transfected and plated in serum-free media in trans-well chambers for 3 hours. Media containing varying concentrations of FBS (0.1% 
to 10%) were placed in the lower chambers. One-way ANOVA with Tukey's post-test was used to determine statistical significance (P < 0.05) 
between the following: con and siSTAT5b (*), siLuc and siSTAT5b (black circles); n = 3. (c) MDA-MB-231 cells were transfected with no siRNA 
(con), control siRNA for luciferase (siLuc), or siRNA specific to STAT5a/b (siSTAT5b siGENOME SMARTpool), STAT5a (siSTAT5a custom oligonu-
cleotide), or STAT5b (siSTAT5b siGENOME SMARTpool oligonucleotide 3), and trans-well migration assays were performed as described. One-
way ANOVA with Tukey's post-test was used to determine statistical significance (P < 0.05) between the following: con and siSTAT5a/b (*), con 
and siSTAT5b (*), siLuc and siSTAT5a/b (black circles), siLuc and siSTAT5b (black circles); n ≥ 5. (a and c) Whole-cell lysates from siRNA-trans-
fected cells were immunoblotted with antibodies specific for STAT5a, STAT5b, and β-actin as a loading control.Available online http://breast-cancer-research.com/content/11/4/R52
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Because STAT5a has been implicated in breast cancer migra-
tion [10], we investigated the role of STAT5a on migration in
our model system. We chose to use the MDA-MB-231 breast
cancer cell line because they are highly migratory and express
both STAT5a and STAT5b proteins, whereas BT-549 breast
cancer cells express only STAT5b (data not shown). To target
STAT5b specifically in the MDA-MB-231 cells, we used one
of the individual oligonucleotides from the SMARTpool, which
had no effect on STAT5a levels (Figure 1C, lane 5). The total
SMARTpool, previously used in the BT-549 cells, was used to
determine the effect of dual knockdown of STAT5a and
STAT5b in our MDA-MB-231 model system. Whereas knock-
down of STAT5b inhibited migration of MDA-MB-231 cells by
greater than 50%, knockdown of STAT5a had no significant
effect on migration of these cells (Figure 1C). Furthermore,
knockdown of STAT5a in combination with STAT5b did not
enhance the inhibition of migration due to knockdown of
STAT5b alone. Therefore, STAT5b is necessary for optimal
migration of highly aggressive breast cancer cells, whereas
expression of STAT5a is not required and cannot compensate
for loss of STAT5b.
To eliminate the possibility of off-target effects of STAT5b
knockdown, we performed knockdown-rescue experiments.
MDA-MB-231 cells were simultaneously transfected with
STAT5b-specific siRNA and hemagglutinin (HA)-tagged wild-
type STAT5b that is resistant to knockdown. Consistent with
previous experiments, knockdown of STAT5b inhibited migra-
tion of MDA-MB-231 cells by approximately 60%. Re-intro-
duction of wild-type STAT5b restored migration to
approximately 76% of control levels (Figure 2B), confirming
that the inhibition of migration with STAT5b knockdown is due
to a direct effect of STAT5b on migratory pathways. In these
experiments, transfection efficiency of siRNA was close to
100%, whereas transfection efficiency of rescue constructs
was approximately 65% to 75% (data not shown).
Expression of wild-type, Y699F-, or dominant-negative 
STAT5b rescues migration, but expression of R618K-
STAT5b does not
Additional knockdown-rescue experiments were performed to
identify the functional domains required for rescue of the
siRNA phenotype. We introduced Y699F-, dominant-negative
(dn)-, and R618K-STAT5b mutants to test the requirement of
transcriptional activity and active Y699-SH2 STAT5b dimers
for promoting migration. Y699F-STAT5b cannot be phospho-
rylated on the conserved tyrosine residue Y699, and dn-
STAT5b lacks the C-terminal transactivation domain, render-
ing these constructs transcriptionally inactive [14,17,20].
R618K-STAT5b has a mutation in the conserved arginine
required for SH2 domains to bind phosphorylated tyrosines,
interfering with the ability of this mutant to form active dimers
with Y699-phosphorylated STAT5b [21]. In migration assays,
re-introduction of Y699F- and dn- STAT5b into MDA-MB-231
cells rescued migration to the same level as did rescue with
Figure 2
Expression of wild-type, Y699F-, or dominant-negative STAT5b res- cues migration, but expression of R618K-STAT5b does not Expression of wild-type, Y699F-, or dominant-negative STAT5b res-
cues migration, but expression of R618K-STAT5b does not. (a) 
Domain structure of the STAT5b protein depicting the amino terminus 
(N-term), DNA-binding domain (DBD), Src homology 2 domain (SH2), 
transactivation domain (TAD), and the location of the conserved tyro-
sine residue, Y699, and arginine residue, R618. (b) MDA-MB-231 
breast cancer cells were transfected with control siRNA to luciferase 
(siLuc) or siRNA specific to STAT5b (siSTAT5b siGENOME SMART-
pool oligonucleotide #3) alone or in the presence of HA-tagged wild-
type (wt-STAT5b), Y699F (YF-STAT5b), dominant-negative (dn-
STAT5b), or R618K (RK-STAT5b) STAT5b constructs engineered to 
be immune to siRNA knockdown. Seventy-two hours after transfection, 
trans-well assays were performed for 6 hours, as described in Figure 1. 
Results are graphed as relative migration, compared with siLuc control. 
One-way ANOVA with Tukey's post-test was used to determine statisti-
cal significance (p < 0.05) between the following: siLuc and siSTAT5b 
(*), siSTAT5b and siSTAT5b + wt-STAT5b (black circles), siSTAT5b 
and siSTAT5b + YF-STAT5b (black circles), siSTAT5b and siSTAT5b 
+ dn-STAT5b (black circles); n ≥ 4. Comparison of siSTAT5b and 
siSTAT5b + RK-STAT5b was not statistically significant. Whole-cell 
lysates from transfected cells were immunoblotted with antibodies spe-
cific for STAT5b, HA, or β-actin as a loading control.Breast Cancer Research    Vol 11 No 4    Bernaciak et al.
Page 6 of 11
(page number not for citation purposes)
wild-type STAT5b. In contrast, the R618K-STAT5b mutant
could not rescue migration (Figure 2B). Taken together, these
data indicate that STAT5b-mediated transcription is not nec-
essary for regulating migration. Moreover, the SH2 domain has
an integral role, separate from that of active dimer formation, in
promoting migration.
STAT5b knockdown inhibits β1-integrin-mediated 
migration to FN
We sought to determine the serum component responsible for
migration of breast cancer cells as a means of gaining insight
into those migratory signaling pathways to which STAT5b
contributes. Despite previously published work, we did not
observe migration of BT-549 or MDA-MB-231 cells to the
chemokine stromal cell-derived factor-1β (SDF-1β) [22]. In
addition, no migration was observed to lysophosphatidic acid
(LPA), a major component of serum. Interestingly, in the
absence of serum, neither cell line migrated to epidermal
growth factor (EGF), despite expression of the epidermal
growth factor receptor (EGFR). We showed previously that
EGF stimulation of breast cancer cells leads to phosphoryla-
tion of STAT5b on Y699 and subsequent transcriptional activ-
ity [13,14,16,17]. Therefore, the lack of migration to EGF is
consistent with the observation that Y699 phosphorylation
and active transcription is not required for the STAT5b migra-
tory function. Additionally, we did not detect either basal or
serum-induced Y699 phosphorylation in these cells, further
supporting the idea that STAT5b mediates migration to serum
through a separate, transcription-independent pathway.
Next, we tested migration of cells to extracellular matrix com-
ponents known to be present in serum, specifically fibronectin
(FN) and vitronectin (VN). Both BT-549 and MDA-MB-231
cells migrated to FN, whereas only BT-549 cells migrated sig-
nificantly to VN (Figure 3A). Therefore, to compare effects on
both cell lines, we used fibronectin as the migratory stimulus.
Cells attach to fibronectin and mediate signaling through
integrin receptors comprising β1-integrin in combination with
various α-integrins. To confirm that fibronectin was indeed a
major serum component stimulating migration, we pretreated
cells with a β1-integrin blocking antibody and measured migra-
tion to serum. Inhibition of β1-integrin receptor inhibited migra-
tion of both cell lines to serum by approximately 50%
compared with the vehicle control (Figure 2B).
Nonspecific mouse IgG had no effect on migration (data not
shown). Fibronectin dose curves were performed, and it was
found that optimal migration of both BT-549 and MDA-MB-
231 cell lines occurred at 2 to 3 μg/ml FN (data not shown).
This is consistent with a study by Hayman and colleagues
[23], which measured the level of FN in fetal bovine serum to
be 25 μg/ml, or 2.5 μg/ml in 10% FBS/DMEM. To determine
whether STAT5b is important in β1-integrin-mediated migra-
tion, we examined the effect of STAT5b knockdown on migra-
tion to FN. Knockdown of STAT5b inhibited migration of both
cell lines to FN, to the same extent that knockdown inhibited
migration to serum, approximately 40% to 60% (Figure 3C).
Taken together, these results demonstrate that STAT5b is
integral for β1-integrin-mediated migration of breast cancer
cells to FN.
STAT5b knockdown results in multiple protrusions and 
negatively affects directionality during wound closure
Wound-healing assays were performed to examine cell mor-
phology and motility during wound closure of cells plated on
FN. After STAT5b knockdown, wounds were allowed to close
for 6 hours, and time-lapse microscopy was used to track cell
movement into the wound. Figure 4A depicts the paths of cells
(tracked by single cell nuclei) along the wound edge. Control
cells migrated in relatively straight lines into the wound area. In
contrast, STAT5b-knockdown cells showed compromised
directionality in movement, migrating both horizontally and ver-
tically. To quantitate these results, we measured migration rate
and directional persistence (Figure 4B and 4C). Knockdown
of STAT5b had little effect on overall migration rate; however,
cells deficient in STAT5b exhibited significant loss of direc-
tional persistence. Additionally, the number of cells with Golgi
localized between the nucleus and leading edge during wound
closure was significantly less after STAT5b knockdown (data
not shown), suggestive of a defect in cell polarity. This is con-
sistent with findings that STAT5b-knockdown cells migrate
less efficiently in transwell assays (Figure 1).
To examine focal adhesion and actin dynamics at the mem-
brane, total internal reflection fluorescence (TIRF) microscopy
was used to image cells plated on FN. STAT5b-knockdown
cells spread slightly faster on FN and exhibited a striking phe-
notype characterized by the formation of multiple irregular pro-
trusions (Figure 5). Knockdown cells were highly contractile
and displayed increased retrograde movement of cell adhe-
sions. Analysis of focal adhesion turnover revealed that control
cells underwent normal focal adhesion turnover, with small
adhesions present at the leading edge, and mature, stable
adhesions located farther inside the cell (Figure 5B). STAT5b-
knockdown cells readily formed adhesions at the leading edge
of protrusive lamellipodia, but over time, these protrusions
contracted, and the adhesions underwent retrograde flow
back into the cell (Figure 5B). As a whole, these data suggest
that STAT5b contributes to the coordinated regulation of pro-
trusive and contractive processes.
Discussion
The work presented here establishes an important, previously
undiscovered role for STAT5b in the migration of highly
aggressive breast cancer cells. Knockdown of STAT5b inhib-
its migration of BT-549 and MDA-MB-231 human breast can-
cer cells to serum and fibronectin (Figures 1 and 3). This
inhibition can be rescued by expression of wt-, Y699F-, or dn-
STAT5b, but not with the SH2 domain mutant R618K-
STAT5b (Figure 2). Upon attachment to fibronectin, STAT5b-Available online http://breast-cancer-research.com/content/11/4/R52
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Figure 3
STAT5b knockdown inhibits β1-integrin-mediated migration to fibronectin (FN) STAT5b knockdown inhibits β1-integrin-mediated migration to fibronectin (FN). (a) The undersides of trans-well filters were coated with 10 μg/ml 
FN or vitronectin (VN) overnight at 4°C. BT-549 and MDA-MB-231 cells were placed in serum-free media in upper chambers, and 1% fetal bovine 
serum (FBS) (BT-549) or 10% FBS (MDA-MB-231) medium was placed in the lower chambers for FBS controls. Serum-free medium was placed in 
lower chambers for FN and VN conditions. Migration was allowed to proceed for 3 hours (BT-549) or 6 hours (MDA-MB-231) (n = 3). (b) BT-549 
and MDA-MB-231 cells were pretreated for 1 hour at 37°C with 10 μg/ml β1-integrin-blocking antibody or DMSO control (con). Cells were plated in 
trans-well chambers in the presence of blocking antibody, and migration to 1% FBS (BT-549) or 10% FBS (MDA-MB-231) was measured. Stu-
dent's t test was used to determine statistical significance (P < 0.05) between the following: BT-549: con and antibody (*) (n = 6); MDA-MB-231: 
con and antibody (*) (n = 4). (c) The undersides of trans-well filters were coated with 3 μg/ml FN overnight at 4°C, and migration assays were per-
formed with siRNA-transfected cells as described in part a. One-way ANOVA with Tukey's post-test was used to determine statistical significance 
(P < 0.05) between the following: BT-549: siLuc and siSTAT5b FBS (*), siLuc and siSTAT5b FN (black circles); n = 4. MDA-MB-231: siLuc and 
siSTAT5b FBS (*), siLuc and siSTAT5b FN (black circles); n = 3.Breast Cancer Research    Vol 11 No 4    Bernaciak et al.
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knockdown cells form multiple, contractile protrusions result-
ing in loss of directionality and inefficient migration (Figures 4
and 5).
Knockdown of STAT5b inhibits migration of both BT-549 and
MDA-MB-231 breast cancer cell lines to serum, whereas
knockdown of STAT5a has no effect (Figure 1). These results
may seem contradictory to those published by Sultan and col-
leagues [10], which reported a suppressive effect of STAT5a
on breast cancer cell migration. However, in those studies,
STAT5a was overexpressed in the moderately migratory BT-
20 and T-47D breast cancer cell lines, which contain little to
no endogenous STAT5a. The STAT5a and STAT5b expres-
sion pattern in those cell lines is very different from that seen
in MDA-MB-231 cells, and consequently, the signaling may
differ. Moreover, the role of endogenous STAT5b was not
investigated in the studies of Sultan and associates. We and
others found that STAT5b is the predominant STAT5a/b pro-
tein expressed in breast cancer cell lines and tissues, and that
STAT5b, not STAT5a, mediates proliferation of breast cancer
cells [10,14,16]. Differential expression or activity (or both) of
STAT5a and STAT5b has been reported in other cancer
model systems [9,24,25]. STAT5b levels and phosphorylation
are elevated in SCCHN tumors compared with control
mucosa, whereas STAT5a levels to do not change [24]. Con-
sistent with these findings, antisense inhibition of STAT5b, but
not STAT5a, inhibits in vivo growth of SCCHN xenografts
[24]. In prostate cancer, differential STAT5a and STAT5b pro-
tein expression can be correlated with metastatic potential.
STAT5a is expressed in nonmetastatic C1D mouse prostate
cancer cells, but not in their metastatic C2H counterparts,
whereas STAT5b is expressed in both [9]. Additionally,
STAT5a is expressed in LNCaP human prostate cancer cells
but not the more highly migratory PC-3 prostate cancer cell
line, but STAT5b levels are comparable [9]. For these reasons,
it is imperative to determine the individual contributions of
STAT5a and STAT5b, as they may have distinct functions in
tumorigenesis.
After establishing the necessity of STAT5b for maximal migra-
tion of breast cancer cells to serum, we investigated the mech-
anism by which this occurs. Interestingly, the migratory
function of STAT5b does not require phosphorylation at tyro-
sine 699 (Y699) or the C-terminal transactivation domain
(TAD), evidenced by equivalent rescue of migration with either
wt-, Y699F-, or dn-STAT5b (Figure 2). Phosphorylation of
Y699 is a hallmark of STAT5b transcriptional activation. If this
residue is mutated to a phenylalanine, such that it cannot be
phosphorylated (Y699F), the resulting STAT5b mutant is tran-
scriptionally inactive [17,20]. Dn-STAT5b is also transcription-
ally inactive because of the loss of the TAD and the ability to
bind transcriptional cofactors [14]. Although STAT proteins
are predominantly thought of as transcription factors that func-
tion in the nucleus, recent work identified a non-transcriptional,
cytoplasmic role for unphosphorylated STAT3 in regulating
Figure 4
STAT5b knockdown negatively affects directionality during wound clo- sure STAT5b knockdown negatively affects directionality during wound clo-
sure. Wounds were made in confluent monolayers of siRNA-trans-
fected BT-549 cells, and time-lapse microscopy was used to track cell 
movement into the wound over a 6-hour period. (a) Progressive line 
images tracking single cell nuclei of cells along the wound edge. Two 
independent experiments are shown. (b) Migration rate (μm/h) was cal-
culated by dividing the length of the migration path by the total movie 
time. (c) Directional persistence (D/T) was determined as the net dis-
placement (D) divided by the total length of the migration path (T). (b, c) 
Values from at least four independent experiments were used for calcu-
lations (siLuc, n = 24; siSTAT5b, n = 32). Student's t test was used to 
determine statistical significance (p < 0.05) between siLuc and 
siSTAT5b (*). Comparisons of migration rate were not statistically sig-
nificant.Available online http://breast-cancer-research.com/content/11/4/R52
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Figure 5
STAT5b-knockdown cells exhibit multiple protrusions with increased retraction STAT5b-knockdown cells exhibit multiple protrusions with increased retraction. BT-549 cells were transfected with siRNA (siLuc or siSTAT5b), 
GFP-speckle-actin, and mKO-paxillin. Seventy-two hours after transfection, cells were plated on 3 μg/ml fibronection (FN) for 20 to 30 minutes, and 
TIRF time-lapse microscopy was performed. Images were taken every 3 seconds for 5 minutes at 60× magnification. (Line indicates 10 μm). (a) Still 
images representing actin and paxillin staining in control (siLuc) and STAT5b-knockdown (siSTAT5b) cells at start of filming (0 min) and end of film-
ing (5 min). (b) Enlarged images depicting boxed areas from part a. Arrows identify single focal adhesions at each time point. (c) Protrusion rate 
(μm/min) was calculated as the length of the protrusion divided by the total time of the movie for at least three independent experiments (siLuc, n = 
16; siSTAT5b, n = 13). Student's t test was used to determine statistical significance (P < 0.05) between siLuc and siSTAT5b (*).Breast Cancer Research    Vol 11 No 4    Bernaciak et al.
Page 10 of 11
(page number not for citation purposes)
tubulin dynamics [26]. Unphosphorylated STAT dimers take
on an antiparallel configuration through interactions between
the DNA-binding domains [27,28]. In this conformation, the
SH2 domains are on opposite sides of the structure and are
free to interact with phosphorylated tyrosines of other pro-
teins. The necessity of the SH2 domain of STAT5b in migra-
tion is consistent with a cytoplasmic function of
unphosphorylated STAT5b. We propose that STAT5b uses its
SH2 domain to act as a scaffolding protein, bringing together
signaling molecules necessary for efficient, directional migra-
tion. Although migration is inhibited to similar levels after
STAT5b knockdown or blocking of β1-integrin (Figure 3), it
remains to be determined whether STAT5b interacts directly
with β1-integrin or if this effect is indirect. There are many tyro-
sine-phosphorylated proteins in the cytoplasm involved in
migratory signaling with which STAT5b may interact, and
future studies are aimed at uncovering these associations.
Loss of STAT5b leads to a polarity defect that impedes direc-
tional movement (Figure 4). During spreading on fibronectin,
STAT5b-knockdown cells take on a remarkable phenotype
distinguished by the formation of multiple, unstable protru-
sions (Figure 5). No defect is found in initial attachment, and
once attached, protrusions extend rapidly. However, these
protrusions are highly dynamic, and over time, they contract
back into the cell. This phenotype is indicative of disrupted
equilibrium between Rho family GTPases. Rac is localized pre-
dominantly at the leading edge, with Rho in the tail. Normal
ratios of Rho and Rac lead to Rac-mediated formation and
spreading of broad lamellipodia in the front of the cell, followed
by Rho-mediated tail retraction, overall resulting in directional
migration toward a stimulus [29]. Increased Rho activity in the
front of the cell would disrupt this equilibrium and could
account for the multiple protrusions and increased contraction
at the front of the cell seen with STAT5b knockdown. Based
on the data presented here, we postulate that unphosphor-
ylated STAT5b mediates migration of breast cancer cells
through regulation of cytoplasmic Rho GTPase family signal-
ing.
In summary, these studies are the first to report a role for
STAT5b in the migration of breast cancer cells. It is well estab-
lished that STAT5b positively regulates breast cancer cell pro-
liferation and survival, two processes important for initial tumor
formation and growth. These data implicate STAT5b in the
later stages of tumorigenesis also, such as migration. Future
studies will further elucidate the mechanism by which STAT5b
exerts its effect on migration, thereby broadening our under-
standing of how STAT5b promotes tumorigenesis and possi-
bly metastasis. This will facilitate the long-term goal of defining
conditions whereby STAT5b would be an effective therapeutic
target for the treatment of breast cancer.
Conclusions
Our studies demonstrate a novel function of STAT5b in breast
cancer cell migration. The importance of STAT5b in mediating
breast cancer cell proliferation and survival has already been
established. This work is the first to show a positive regulatory
role for STAT5b in breast cancer cell migration. Therefore,
STAT5b not only may function in the initiation of tumorigene-
sis, through its pro-proliferative and pro-survival signaling, but
also may promote tumor progression by mediating migration.
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